Issue 1, 2025

Remarkable utilization of quinazoline-based homosulfonamide for in vitro cytotoxic effects with triple kinase inhibition activities: cell cycle analysis and molecular docking profile

Abstract

We tested newly synthesized compounds 1–13 on 59 cancer cell lines and found that acylhydrazones 5, 6, 7, 9, and 12 showed the best in vitro cytotoxic activity. They stopped the mean growth percentage (MG%) by an average of 23.5, 55.2, 89.4, 88.5, and 88.4%, respectively. Compound 5 was subjected to NCI tests at five-dose dilutions on 59 tumor cells. It is more effective in killing tumor cells than gefitinib (mean GI50: 7.7 μM) and erlotinib (mean GI50: 2.1 μM). Its mean GI50 value was 1.0 μM, and its LC50 value was over 100 μM, whereas gefitinib's was 95.6 μM and erlotinib's was 14.3 μM. Its TGI was 89.2 μM, while those drugs were 66.3 and 14.3 μM, respectively. We evaluated acylhydrazones 5, 6, 7, 9, and 12 for dose-dependent enzymatic inhibition of EGFR, HER2, and CDK9 kinases to study the mechanism of the in vitro cytotoxicity. With IC50 values of 84.4 and 51.5 nM, compounds 5 and 6 are the most potent EGFR inhibitor analogs, similar to Gefitinib (IC50 of 53.1 nM). Compounds 5, 6, and 12 blocked HER2 like Gefitinib did (IC50 = 38.8 nM); their IC50 values were 53.9, 44.1, and 110.6, respectively. Compounds 5, 6, and 7 had IC50 values of 146.9, 96.1, and 155.4 nM, which means they blocked CDK9 activity almost as well as Dinaciclib (IC50 53.1 nM). Flow cytometers count the amount of DNA in T-47D and MOLT4 cells treated with compounds 5 and 6. The IC50 value of compound 5 increases from 6.6% for the DMSO/T-47D control to 26.3% in the G2-M phase, while compound 6 goes from 61.4 for the DMSO/MOLT4 control to 89.0% in the G1 phase. The tested compounds cause early death, ranging from 0.4% and 0.6% (a DMSO control sample) to 9.3% and 19.2%, respectively. Derivatives 5 and 6 also increased late death from 0.1 to 14.8% and 12.6 to 0.3%, respectively, favoring the apoptotic route over the necrotic one for cell death to 50.5 μM. When tested for cell death against the standard WI-38 fibroblast cell line, imines 5 and 6 were less toxic than doxorubicin.

Graphical abstract: Remarkable utilization of quinazoline-based homosulfonamide for in vitro cytotoxic effects with triple kinase inhibition activities: cell cycle analysis and molecular docking profile

Supplementary files

Article information

Article type
Paper
Submitted
05 Oct 2024
Accepted
26 Dec 2024
First published
06 Jan 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 541-558

Remarkable utilization of quinazoline-based homosulfonamide for in vitro cytotoxic effects with triple kinase inhibition activities: cell cycle analysis and molecular docking profile

A. S. El-Azab, A. A.-M. Abdel-Aziz, A. H. Bakheit, H. M. Alkahtani, A. J. Obaidullah, M. M. Hefnawy and I. A. Al-Suwaidan, RSC Adv., 2025, 15, 541 DOI: 10.1039/D4RA07174C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements